Trial Profile
Treatment Patterns And Clinical Outcomes Among Patients Receiving Palbociclib Combinations For Hr+/her2- Advanced/Metastatic Breast Cancer In Real World Settings
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Aromatase inhibitors; Fulvestrant; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms IRIS
- Sponsors Pfizer
- 28 Nov 2022 Results assessing the effectiveness of palbociclib in real world, published in the Clinical Therapeutics.
- 03 Dec 2021 Results (n=2954) presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 05 Oct 2020 Status changed from active, no longer recruiting to completed.